Skip to main content
OpenTrials
Completed

NCT Number: NCT06309212

Assessing the Impact of COVID-19 on HMPV Incidence and Severity Among Adults

Human metapneumovirus (HMPV) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. This study investigates the prevalence, clinical characteristics, and post-COVID-19 trends of HMPV infection among adults in Istanbul, Turkey.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

The Prevalance of HMPV After COVID-19 Pandemic The Importance of Accurate Diagnosis for HPMV

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Acibadem University

Istanbul, Turkey (Türkiye)

About this study

Human metapneumovirus (HMPV) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. This study investigates the prevalence, clinical characteristics, and post-COVID-19 trends of HMPV infection among adults in Istanbul, Turkey.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults >18 years
  • Patients with acute respiratory tract infection symptoms
  • Patients who underwent multiplex PCR testing for respiratory viruses

Exclusion criteria

  • Patients for whom no respiratory viral panel test was conducted

Treatment and study plan

observation

Other

Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay

Primary outcomes

  1. Prevalence of HMPV infection in adults pre- and post-COVID-19 pandemic

    Time frame: Between 2016-2020 (pre-COVID) and 2021-2023 (post-COVID)

    Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay

Secondary outcomes

  1. Comparison of HMPV with other respiratory viruses in adults

    Time frame: Between 2016-2020 (pre-COVID) and 2021-2023 (post-COVID)

    Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay

Sponsors and collaborators

Lead sponsor

Acibadem University

Other

Registry information

Important dates

Study start
2023
Primary completion
2023
Study completion
2024
First posted
Mar 13, 2024
Registry last updated
Mar 13, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.